Compare Heron Therapeutics Inc (HRTX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Noble Corporation plc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Noble Corporation plc trades at $40.19 (market cap $6.73B). The key difference: Noble Corporation plc is far larger — about 99× Heron Therapeutics Inc's market cap, and Noble Corporation plc pays a 4.74% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Noble Corporation plc for 26 Days on average.
| HRTX | NE | |
|---|---|---|
Market Cap | $68.01M | $6.73B |
Volume | 1,891,941 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $1.49 | $54.37 |
52-Week Low | $0.27 | $26.70 |
Typical Hold Time | 35 Days | 26 Days |
Enterprise Value | $174.75M | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Noble Corporation (NE) trades at $40.97, down 1.16% on the day, with a bearish technical signal driven by moving averages and ADX indicators. The stock's valuation shows a P/E of 43.59 and P/S of 2.14, while recent earnings have been mixed with two misses and one beat in the last three quarters. A long-term drilling contract in Ghana provides operational stability, but investor sentiment is tempered by an ongoing legal investigation noted in recent news.
The outlook for NE is cautious; analyst consensus is a Buy with a $52 price target, implying potential upside, but risks include earnings volatility and legal scrutiny. Positive cash flow and a dividend payment support income investors, yet the bearish technical trend and declining revenue in 2026 warrant close monitoring for any fundamental deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
